FIELD: therapeutic products. SUBSTANCE: spherical or lens-shaped granules with unique maximum diameter 0.5 to 4 mm consist of, wt %: at least one biologically-active compound, 0.1-87; at least one water-insoluble polymer, 5-50; at least one lipophilic component as plasticizer for above polymer, 5-45; naturally occurred or semisynthetic polymer gel former, 0-50; and one or several standard adjuvants. Gel former is a water-soluble cellulose derivative or water-soluble polysaccharide or their mixtures. Granules are prepared by extruding molten mixture of components at 50 to 200 C involving continuous shaping. EFFECT: enabled controlled complete release of active principle according to delayed profile. 8 cl, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING COATED TABLETS | 1995 |
|
RU2177310C2 |
| SOLID MEDICINAL FORMS PREPARING BY EXTRUSION OF ISOMALT-CONTAINING POLYMER MELT AND ACTIVE SUBSTANCE | 1996 |
|
RU2197228C2 |
| SOLID, PARTIALLY OR FULLY FROTHED PREPARATIONS OF ACTIVE COMPONENT | 1997 |
|
RU2200004C2 |
| EXTRUSION OF HOT LIQUID OF MULTIPLE PARTICLES WITH MODIFIED RELEASE | 2009 |
|
RU2483713C2 |
| PHARMACEUTICAL COMPOSITION FOR HIV INFECTION TREATMENT | 2016 |
|
RU2619840C1 |
| HEPARIN-BASE FORMULATION | 2001 |
|
RU2278658C2 |
| SUSTAINED-RELEASE MICROTABLET CONTAINING DERIVATIVES OF β-PHENYLPROPIOPHENONE | 1994 |
|
RU2157191C2 |
| MESALAZINE-BASE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH SUSTAINED-RELEASE ACTIVE COMPONENT | 2000 |
|
RU2245148C2 |
| SOLID MEDICINAL FORMULA FOR ORAL USE SHOWING THE DELAYED RELEASE OF AN ACTIVE SUBSTANCE AND A METHOD OF ITS MAKING (VARIANTS) | 1991 |
|
RU2101009C1 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
